Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination

The yellow fever (YF) vaccine consists of an attenuated virus, and despite its relative safety, some adverse events following YF vaccination have been described. At the end of 2016, Brazil experienced the most massive sylvatic yellow fever outbreak over the last 70 years and an intense campaign of Y...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2019-12, Vol.7 (4), p.206
Main Authors: Rezende, Izabela Maurício de, Alves, Pedro Augusto, Arruda, Matheus Soares, Gonçalves, Andreza Parreiras, Oliveira, Gabriela Fernanda Garcia, Pereira, Leonardo Soares, Dutra, Maria Rita Teixeira, Campi-Azevedo, Ana Carolina, Valim, Valéria, Tourinho, Renata, Oliveira, Jaquelline Germano de, Calzavara, Carlos Eduardo, Said, Rodrigo Fabiano do Carmo, Kroon, Erna Geessien, Martins-Filho, Olindo Assis, Teixeira-Carvalho, Andrea, Drumond, Betânia Paiva
Format: Article
Language:English
Subjects:
5' Untranslated Regions
Adverse events
Amplification
Disease
Epidemics
Fever
Gene amplification
Gene sequencing
Genotypes
Genotyping
Immunization
Infections
Investigations
Nucleotides
Phylogenetics
Phylogeny
Vaccination
Vaccines
Vector-borne diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The yellow fever (YF) vaccine consists of an attenuated virus, and despite its relative safety, some adverse events following YF vaccination have been described. At the end of 2016, Brazil experienced the most massive sylvatic yellow fever outbreak over the last 70 years and an intense campaign of YF vaccination occurred in Minas Gerais state in Southeast Brazil from 2016 to 2018. The present study aimed to develop a genotyping tool and investigate 21 cases of suspected adverse events following YF vaccination. Initial in silico analyses were performed using partial NS5 nucleotide sequences to verify the discriminatory potential between wild-type and vaccine viruses. Samples from patients were screened for the presence of the YFV RNA, using 5'UTR as the target, and then used for amplification of partial NS5 gene amplification, sequencing, and phylogenetic analysis. Genotyping indicated that 17 suspected cases were infected by the wild-type yellow fever virus, but four cases remained inconclusive. The genotyping tool was efficient in distinguishing the vaccine from wild-type virus, and it has the potential to be used for the differentiation of all yellow fever virus genotypes.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines7040206